Symetis touts positive findings for its Acurate TA TAVI system

April 4, 2013 by Arezu Sarvestani

Swiss device maker Symetis reports promising 30-day outcomes from its Acurate TA transcatheter aortic valve implantation postmarket registry.

Symetis logo

Swiss medical device maker Symetis released 30-day registry findings for its 2nd-generation transcatheter aortic valve implantation systems, touting high procedural success rates and minimal valve leakage.

Results from the SAVI postmarket registry highlighted findings from the 1st 250 patients implanted with Symetis' Acurate TA TAVI system, which won European regulatory approval in September 2011.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.